Teva Has Earned Nothing,' US FDA Tells Court In Battle Over Generic Restasis 180-Day Exclusivity :: Pink Sheet
Retailers File Lawsuit Against Allergan over Restasis Patents | BioSpace
FDA Set To Make Key Decision On Restasis Generics :: Generics Bulletin
Allergan settles Restasis litigation with Pfizer's InnoPharma as backlash mounts over tribal patent deal | FiercePharma
Teva Gets a Head Start Over Rivals With Launch of HIV Generics; Analyst Says 'Buy'
Teva completes acquisition of Allergan's generics business
8. Restasis | FiercePharma
Allergan's Restasis Will Soon be Open to Generic Copycats After Ruling in Patent Case - Xtalks
Allergan heads to federal court to defend Restasis against early generic rivals | FiercePharma
Court throws out Allergan's patent deal with Native American tribe - PMLiVE
Allergan settles Restasis patent challenge after moving patents to Native American tribe - MassDevice
US federal judge invalidates Allergan patents on Restasis - Pharmaceutical Business review
Teva Sues US FDA To Obtain 180-Day Exclusivity For Its Generic Restasis :: Pink Sheet
Allergan loses Restasis patent protections in federal court decision | FiercePharma
Allergan Unhappy with Patent Office Decision to Allow Mylan Challenge to Restasis Patents - TheStreet
7. Restasis | FiercePharma
Xiidra vs. Restasis: Differences, similarities, and which is better for you
US Court rejects Teva's lawsuit over generic Restasis
In a New Twist in Restasis Legal Battle, Teva Sues the FDA
Allergan, Inc. v. Teva Pharms.: Federal Court Invalidates Allergan Patents as Obvious - Harvard Journal of Law & Technology
Teva Canada Announces the Launch of Teva-Cyclosporine® Ophthalmic Emulsion, the First Generic Version of Restasis® in Canada for the Treatment of Dry Eye Disease